Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...

Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of ...

Fred Alger Management, an investment management company, released its “Alger Spectra Fund” fourth quarter 2024 investor ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

We could point out that tirzepatide, the active ingredient in Mounjaro and Zepbound, is still undergoing ... for such products as Alzheimer's disease (AD) treatment Kisunla, ulcerative colitis ...

Kisunla looks particularly attractive due to the significant unmet need in AD. These relatively new approvals ... Even with Eli Lilly's Mounjaro and Zepbound not growing as fast as many ...

The Dow Jones rose Thursday after surprise weekly jobless claims. Nvidia partner Arm stock tumbled on earnings, while Roblox ...

Eli Lilly posts robust Q4 earnings as Mounjaro and Zepbound sales more than double, lifting full-year revenue by 32% ...

Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.